PDB55 Estimating the Cost-Effectiveness of Premixed Analog Insulin Versus Long Acting Analog Basal Insulin and Premixed Human Insulin in the Management of Type 2 Diabetes: A Long Term Analysis in the United Kingdom (UK)

B. Curtis; R. Pollock; J. Smith-Palmer; W. Valentine

doi:10.1016/j.jval.2012.03.976

PDB55 Estimating the Cost-Effectiveness of Premixed Analog Insulin Versus Long Acting Analog Basal Insulin and Premixed Human Insulin in the Management of Type 2 Diabetes: A Long Term Analysis in the United Kingdom (UK)

Value in Health ◽

10.1016/j.jval.2012.03.976 ◽

2012 ◽

Vol 15 (4) ◽

pp. A180

Author(s):

B. Curtis ◽

R. Pollock ◽

J. Smith-Palmer ◽

W. Valentine

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Basal Insulin ◽

The United Kingdom ◽

Analog Insulin ◽

Long Acting ◽

The Cost ◽

Term Analysis

Download Full-text

DB1 EVALUATING THE COST-EFFECTIVENESS OF THERAPY CONVERSION FROM BASAL INSULIN TO BIPHASIC INSULIN ASPART 30/70 IN PATIENTS WITH TYPE 2 DIABETES IN CHINA: A MODELING STUDY OF LONG-TERM COSTS AND HEALTH OUTCOMES

Value in Health ◽

10.1016/s1098-3015(11)73078-9 ◽

2010 ◽

Vol 13 (7) ◽

pp. A507

Author(s):

J Chang ◽

F Sun ◽

H Li

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Health Outcomes ◽

Insulin Aspart ◽

Basal Insulin ◽

Biphasic Insulin ◽

Biphasic Insulin Aspart 30 ◽

The Cost

Download Full-text

The Cost-Effectiveness OF Canagliflozin (Cana) Versus Dapagliflozin (Dapa) In Patients With Type 2 Diabetes Mellitus (T2dm) With Inadequate Control On Metformin (Met) Monotherapy In The United Kingdom

Value in Health ◽

10.1016/j.jval.2014.08.694 ◽

2014 ◽

Vol 17 (7) ◽

pp. A344 ◽

Cited By ~ 2

Author(s):

M. Schroeder ◽

P. Johansen ◽

G. Thompson ◽

M. Willis ◽

C. Neslusan

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

United Kingdom ◽

Cost Effectiveness ◽

The United Kingdom ◽

The Cost

Download Full-text

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom

Cardiovascular Diabetology ◽

10.1186/1475-2840-7-24 ◽

2008 ◽

Vol 7 (1) ◽

pp. 24 ◽

Cited By ~ 27

Author(s):

Anette Woehl ◽

Mark Evans ◽

Anthony P Tetlow ◽

Philip McEwan

Keyword(s):

Type 2 Diabetes ◽

United Kingdom ◽

Cost Effectiveness ◽

Insulin Glargine ◽

The United Kingdom ◽

The Cost

Download Full-text

The Cost-Effectiveness of Canagliflozin (CANA) Versus Dapagliflozin (Dapa) 10mg and Empagliflozin (EMPA) 25mg in Patients with Type 2 Diabetes Mellitus (T2DM) as Monotherapy in the United Kingdom

Value in Health ◽

10.1016/j.jval.2015.09.2098 ◽

2015 ◽

Vol 18 (7) ◽

pp. A607 ◽

Cited By ~ 4

Author(s):

M Schroeder ◽

P Johansen ◽

M Willis ◽

C Neslusan

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

United Kingdom ◽

Cost Effectiveness ◽

The United Kingdom ◽

The Cost

Download Full-text

Long-Term Cost Effectiveness Analysis Of Ideglira Versus Glp-1 Added To Basal Insulin As Intensification Therapies In Type 2 Diabetes Mellitus In Spain

Value in Health ◽

10.1016/j.jval.2016.03.1714 ◽

2016 ◽

Vol 19 (3) ◽

pp. A99

Author(s):

M Prades ◽

L Lizan ◽

B Hunt ◽

A Ramirez de Arellano

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cost Effectiveness ◽

Basal Insulin ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

PDB74 - IDEGLIRA VERSUS IGLARLIXI FOR PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN: A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN THE CZECH REPUBLIC

Value in Health ◽

10.1016/j.jval.2018.09.779 ◽

2018 ◽

Vol 21 ◽

pp. S130-S131

Author(s):

M. Russel-Szymczyk ◽

W. Parekh ◽

K. Rychna ◽

J. Pöhlmann ◽

B. Hunt

Keyword(s):

Type 2 Diabetes ◽

Czech Republic ◽

Cost Effectiveness ◽

Basal Insulin ◽

Cost Effectiveness Analysis ◽

The Czech Republic ◽

Effectiveness Analysis

Download Full-text

A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States

Journal of Medical Economics ◽

10.3111/13696998.2012.675890 ◽

2012 ◽

Vol 15 (4) ◽

pp. 766-775 ◽

Cited By ~ 5

Author(s):

Richard F. Pollock ◽

Bradley H. Curtis ◽

William J. Valentine

Keyword(s):

United States ◽

Cost Effectiveness ◽

Insulin Lispro ◽

The United States ◽

Insulin Analogs ◽

Biphasic Insulin ◽

Long Acting ◽

The Cost ◽

Term Analysis

Download Full-text

Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands

Diabetes Therapy ◽

10.1007/s13300-017-0266-3 ◽

2017 ◽

Vol 8 (4) ◽

pp. 753-765 ◽

Cited By ~ 10

Author(s):

Barnaby Hunt ◽

Divina Glah ◽

Maarten van der Vliet

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

The Netherlands ◽

Basal Insulin ◽

Glycemic Targets

Download Full-text

Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes

Advances in Therapy ◽

10.1007/s12325-008-0069-z ◽

2008 ◽

Vol 25 (6) ◽

pp. 567-584 ◽

Cited By ~ 20

Author(s):

William J. Valentine ◽

Gordon Goodall ◽

Mark Aagren ◽

Steffen Nielsen ◽

Andrew J. Palmer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Detemir ◽

The Cost ◽

Cost Outcomes ◽

Modelling Study

Download Full-text

PCV34 THE COST-EFFECTIVENESS OF ALISKIREN AS ADD ON TO LOSARTAN AND OPTIMAL ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN THE UNITED KINGDOM SETTING

Value in Health ◽

10.1016/s1098-3015(10)70622-7 ◽

2008 ◽

Vol 11 (3) ◽

pp. A196 ◽

Cited By ~ 1

Author(s):

JL Palmer ◽

VC Munk ◽

R Kotchie ◽

G Vincze ◽

Charney k ◽

...

Keyword(s):

Type 2 Diabetes ◽

United Kingdom ◽

Cost Effectiveness ◽

Antihypertensive Therapy ◽

The United Kingdom ◽

The Cost

Download Full-text